Cemex S.A.B. de C.V. Sponsored ADR vs Cytokinetics Inc — how do they compare? Cemex S.A.B. de C.V. Sponsored ADR trades at $9.56 (market cap $13.79B), while Cytokinetics Inc trades at $61.95 (market cap $8.62B). The key difference: Cemex S.A.B. de C.V. Sponsored ADR is the larger of the two by market cap, and Cemex S.A.B. de C.V. Sponsored ADR pays a 1.3% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cemex S.A.B. de C.V. Sponsored ADR for 0 Days and Cytokinetics Inc for 19 Days on average.
| CX | CYTK | |
|---|---|---|
Market Cap | $13.79B | $8.62B |
Volume | 3,993,982 | 2,594,626 |
Sector | Basic Materials | Health |
52-Week High | $13.55 | $87.26 |
52-Week Low | $9.12 | $54.76 |
Typical Hold Time | 0 Days | 19 Days |
Enterprise Value | $19.79B | $8.72B |
Dividend Yield | 1.3% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Cemex produces, distributes, markets, and sells cement, ready-mix concrete, aggregates, and other construction materials. Its operations serve markets around the world.
Read more on CX →Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →